Engineering of N-glycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization (Q38308330)

2 September 2017

title

Engineering of N-glycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization (English)

1 reference

2 September 2017

0 references

1 reference

1 reference

1 reference

Pingfei Li

1

1 reference

2 September 2017

Qi Wan

2

1 reference

2 September 2017

Yong Feng

3

1 reference

2 September 2017

Min Liu

4

1 reference

2 September 2017

Jianguo Wu

5

1 reference

2 September 2017

Xinwen Chen

6

1 reference

2 September 2017

Xiao-Lian Zhang

7

1 reference

2 September 2017

language of work or name

English

0 references

publication date

18 October 2006

1 reference

2 September 2017

1 reference

2 September 2017

volume

25

1 reference

2 September 2017

issue

8

1 reference

2 September 2017

page(s)

1544-1551

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Pathogenesis, diagnosis and management of hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

7 January 2021

Therapy of Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Interaction of hepatitis C virus proteins with host cell membranes and lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Processing of the E1 glycoprotein of hepatitis C virus expressed in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Glycosylation of hepatitis C virus envelope proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Assembly of asparagine-linked oligosaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Folding and assembly of viral membrane proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

A role for carbohydrates in immune evasion in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Induction of HIV‐1 envelope (gp120)‐specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell‐derived gp120 is enhanced by enzymatic removal of N‐linked glycans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Nonlinear partial differential equations and applications: Genomic analysis of the host response to hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

CD81 is required for hepatitis C virus glycoprotein-mediated viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

CD81 is an entry coreceptor for hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Analysis of a successful immune response against hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Neutralizing antibody response during acute and chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.091

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.09.091

1 reference

2 September 2017

1 reference